Study of a new drug for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to perform daily activities with some help or fully (ECOG 0 or 1).
- You must have advanced or metastatic breast, ovarian, or other solid tumor that has progressed on standard treatments.
- You must be willing to provide a tumor tissue or blood sample to check for BRCA or other DNA repair gene mutations.
- You must have at least one tumor that can be measured on scans.
- You must not have had or be using a PARG inhibitor (a type of drug) before or during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
This trial tests a new drug, ART6043, alone or with another drug called olaparib, for people with advanced or metastatic solid tumors. It may help if your cancer has specific DNA repair problems or if you have breast cancer with a BRCA gene mutation.
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.